Specialized lifelong clinical oversight for lung transplant recipients. Providing precise immunosuppressive titration, therapeutic drug monitoring, acute cellular and antibody-mediated rejection diagnostics, opportunistic infection prophylaxis, and functional cardiopulmonary rehabilitation.
High-precision diagnostics, cutting-edge medical technologies, and evidence-based treatment pathways tailored for individual patient outcomes.
The successful completion of lung transplant surgery marks the beginning of a lifelong journey of specialized post-transplant care. Because the human immune system naturally recognizes transplanted donor lungs as foreign tissue, continuous, carefully balanced immunosuppressive medication is mandatory to prevent rejection, while avoiding excessive immunosuppression that could invite opportunistic infections or drug toxicities.
The Post-Lung Transplant Management Program provides lifelong specialized ambulatory and inpatient care. Key clinical components include routine therapeutic drug monitoring (TDM) of immunosuppressive agents, protocol surveillance bronchoscopy with transbronchial lung biopsies, serial home spirometry tracking, and tailored antimicrobial prophylaxis to prevent infection and allograft dysfunction.
Recognizing clinical signs and diagnostic triggers that indicate the need for specialized pulmonary review.
A sudden or persistent drop in home micro-spirometry FEV1 or peak flow is the earliest cardinal clinical warning sign of acute cellular rejection, infection, or airway anastomotic stricture.
Even mild temperature elevations (> 37.8°C / 100°F) in an immunosuppressed transplant recipient must be evaluated immediately for cytomegalovirus (CMV), fungal, or bacterial respiratory infection.
Exertional breathlessness or oxygen desaturation below 95% on pulse oximetry, signaling acute allograft rejection, pleural fluid accumulation, or developing pneumonia.
Production of thick green, yellow, or blood-tinged sputum indicating tracheobronchial pseudomonas colonization, fungal mold infection, or allograft bronchitis.
Elevated serum creatinine or neurological tremors indicating supratherapeutic calcineurin inhibitor (tacrolimus or cyclosporine) levels requiring immediate dose recalculation.
Pleuritic chest pain, discomfort near the thoracotomy scar, or sensations of pleural friction rub requiring urgent chest radiography and clinical assessment.
Advanced medical and surgical equipment providing high-yield diagnostic precision and life-saving therapeutic interventions.
Customized lifelong balance combining a Calcineurin Inhibitor (Tacrolimus / Cyclosporine), an Antimetabolite (Mycophenolate Mofetil / Myfortic / Azathioprine), and low-dose Corticosteroids (Prednisolone).
Scheduled flexible bronchoscopy at 1, 3, 6, and 12 months post-transplant, performing bronchoalveolar lavage (BAL) and transbronchial biopsies (TBBx) to detect subclinical acute cellular rejection.
Meticulous prophylactic regimens against opportunistic pathogens: Valganciclovir for Cytomegalovirus (CMV), Co-trimoxazole (TMP-SMX) for Pneumocystis jirovecii (PCP), and Voriconazole/Posaconazole for Aspergillus.
Proactive phenotypic differentiation between Bronchiolitis Obliterans Syndrome (BOS) and Restrictive Allograft Syndrome (RAS), implementing early azithromycin immunomodulation, Montelukast, and extracorporeal photopheresis (ECP).
Monitoring and interventional management of bronchial donor-recipient anastomotic healing, including balloon dilatation for anastomotic strictures and temporary silicone stent deployment for bronchomalacia.
Targeted physical exercise conditioning, resistance training to counteract steroid-induced muscle myopathy, bone density preservation (DEXA monitoring), and individualized dietary plans.
How we guide every patient from initial assessment to definitive treatment and long-term functional recovery.
Initial stabilization in the transplant ICU (extubation, chest drain removal, mobile ambulation), transition to specialized transplant ward, and intensive patient and family medication education.
Weekly clinic visits, twice-weekly therapeutic drug levels (Tacrolimus/MMF), home spirometry logs review, and scheduled month-1 surveillance bronchoscopy.
Bi-weekly to monthly outpatient clinic consultations, protocol bronchoscopies at month 3, 6, and 12, serial CMV viral monitoring, and gradual tapering of immunosuppression.
Quarterly reviews, annual full-body checkup, skin cancer surveillance, cardiovascular risk optimization, and lifelong open hotline with Dr. Yadav’s transplant team.
Clear, clinically accurate answers to common patient questions regarding this pulmonary specialty.
Yes. Immunosuppressant medications are vital throughout your life to prevent your body's immune system from attacking and destroying the transplanted lungs. Never skip a dose, alter timings, or take any other over-the-counter medicine without consulting the pulmonary team.
Acute Cellular Rejection is an immune reaction where recipient T-lymphocytes infiltrate the donor lung tissue. It is relatively common (occurring in 20-30% of recipients in the first year) and is usually completely reversible when caught early. Treatment typically involves a short 3-day course of high-dose intravenous corticosteroids (methylprednisolone pulse).
Home handheld spirometry allows you to measure your Forced Expiratory Volume in 1 second (FEV1) daily. Changes in lung function often appear on spirometry days or weeks before you feel any breathlessness or cough. A drop of 10% or more from your baseline baseline allows Dr. Yadav to identify rejection or infection at the earliest, most treatable stage.
Absolutely. The goal of transplantation is to return you to a normal, vibrant life. Most recipients return to work within 3 to 6 months post-surgery. Travel is fully encouraged once immune stability is reached (usually after 6 to 12 months), with proper precautions regarding clean water, food safety, and carrying adequate medication.
Grapefruit, pomelo, and Seville oranges must be strictly avoided as they block the liver enzymes that break down tacrolimus, leading to dangerously toxic drug spikes. Many common antibiotics (erythromycin, azithromycin, clarithromycin), antifungals, and pain relievers (NSAIDs like ibuprofen) also alter drug levels and must only be taken with transplant team approval.
Consultation Specialty: Post-Lung Transplant Care
